Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SKB264 Plus Glecirasib in KRAS G12C-Mutated Advanced NSCLC
NCT07670013Phase 2Recruiting
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Apr 2026
- Primary completion
- Jan 2028
- Countries
- 1
01
Overview
A Phase 2 trial of sacituzumab tirumotecan, glecirasib in non-small cell lung cancer (NSCLC), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Started Apr 2026; status: recruiting.
02
Drugs
sacituzumab tirumotecanglecirasib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07670013.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07670013.